Atara Biotherapeutics (ATRA) Cash from Investing Activities (2014 - 2025)

Atara Biotherapeutics has reported Cash from Investing Activities for 12 years, with the latest figure at $8.4 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Investing Activities rose 150.0% year-over-year to $8.4 million; the trailing twelve-month figure through Mar 2026 stood at $949000.0 (down 91.46% YoY), and the FY2025 full-year result was $18.1 million, up 110.44% from the prior year.
• Cash from Investing Activities for Q4 2025 stood at $8.4 million, up from -$2.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $70.4 million in Q3 2023, with the low at -$24.3 million in Q4 2021.
• Historically, Cash from Investing Activities has averaged $18.8 million across 5 years, with a median of $11.7 million in 2021.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 4899.75% — and 2025, when it slumped 170.46%.
• Atara Biotherapeutics' Cash from Investing Activities stood at -$24.3 million in 2021, then jumped by 310.57% to $51.2 million in 2022, then plunged by 80.58% to $9.9 million in 2023, then plunged by 66.05% to $3.4 million in 2024, then soared by 150.0% to $8.4 million in 2025.
• The last three Cash from Investing Activities figures came in at $8.4 million (Q4 2025), -$2.4 million (Q3 2025), and -$5.1 million (Q2 2025), per Business Quant data.